Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 25 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 25 versus QOLIANA.
FENTANYL-25 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia by activating G-protein coupled opioid receptors in the CNS, leading to decreased neurotransmitter release and hyperpolarization of neurons.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
25 mcg/h transdermal patch applied every 72 hours; for opioid-tolerant patients only.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 3-12 hours in elderly, hepatic impairment, or critical illness; context: duration of action shorter due to redistribution.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal (75% as metabolites, <10% unchanged); Fecal (9%); Biliary (minor).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist